SUMATRIPTAN

Course overview

SUMATRIPTAN IS FDA APPROVED AS AN ABORTIVE TREATMENT FOR MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS. ACUTE TREATMENT OF CLUSTER HEADACHE EPISODES CAN BE RELIEVED BY THE ADMINISTRATION OF SUBCUTANEOUS THERAPY. ACCORDING TO CLINICAL STUDIES, SUMATRIPTAN IS AN EFFECTIVE AND WELL-TOLERATED TREATMENT FOR MIGRAINES WHEN GIVEN INTRAVENOUSLY, SUBCUTANEOUSLY, OR ORALLY. IT RELIEVES PHOTOPHOBIA, NAUSEA, HEADACHE, AND FUNCTIONAL DISABILITY. NON-FDA-APPROVED INDICATIONS OF SUMATRIPTAN INCLUDE TREATMENT OF MIGRAINE IN CHILDREN AND ADOLESCENTS. THIS ACTIVITY OUTLINES THE INDICATIONS, MECHANISM OF ACTION, METHODS OF ADMINISTRATION, IMPORTANT ADVERSE EFFECTS, CONTRAINDICATIONS, AND MONITORING, OF SUMATRIPTAN, SO PROVIDERS CAN DIRECT PATIENT THERAPY IN TREATING INDICATED DISORDERS AS PART OF THE INTERPROFESSIONAL TEAM.